Five Prime Therapeutics (FPRX) Receives Media Impact Score of 0.18
News headlines about Five Prime Therapeutics (NASDAQ:FPRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.1984672847133 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Contrasting Five Prime Therapeutics (FPRX) & Dermira (DERM) (americanbankingnews.com)
- RBC Capital Initiates Coverage on Five Prime Therapeutics, Inc. (FPRX) Setting A Rating Of “Outperform” – First News 24 (firstnewspaper24.com)
- Five Prime Therapeutics (FPRX) Announces Licensing Agreement … – StreetInsider.com (streetinsider.com)
- Five Prime Therapeutics, Inc. (FPRX) Receives New Coverage from Analysts at Royal Bank Of Canada (americanbankingnews.com)
- Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics (globenewswire.com)
A number of brokerages have commented on FPRX. Jefferies Group LLC reiterated a “buy” rating and set a $55.00 target price on shares of Five Prime Therapeutics in a report on Thursday, June 8th. Royal Bank Of Canada began coverage on Five Prime Therapeutics in a report on Thursday. They set an “outperform” rating and a $41.00 target price on the stock. BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Five Prime Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $57.50.
Shares of Five Prime Therapeutics (NASDAQ FPRX) opened at 35.81 on Monday. The stock’s 50 day moving average price is $30.75 and its 200 day moving average price is $32.32. The firm’s market cap is $1.00 billion. Five Prime Therapeutics has a 12-month low of $25.97 and a 12-month high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by ($0.43). The company had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. Five Prime Therapeutics’s quarterly revenue was down 16.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.49) EPS. On average, equities research analysts predict that Five Prime Therapeutics will post ($5.16) EPS for the current fiscal year.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.